ARDS
Aridis Pharmaceuticals, Inc.Company Information
- Company Name
- Aridis Pharmaceuticals, Inc.
- CIK
- CIK0001614067
- Category
- <br>Emerging growth company
- Ticker: Exchange
- ARDS: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ARDS
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-06-24
- Last sale
- —
- Shares purchased (TTM)
- 1,428,572
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2023-12-31
- Institutional shares owned
- 6
- Shares outstanding
- 37,428,943
- Ownership
- 0.00%
Earnings Market Reaction
- Filing date
- 2023-11-06
- Price on filing date
- —
- 1-month reaction
- 8.75%
- 3-month reaction
- -5.57%
Balance Sheet
Values in millions ($)| Line item | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 0 | 1 | 5 | 2 | 6 | 12 | 18 | 18 | 4 | 10 | 8 | 6 | ||||||
| Restricted Cash Current | - | - | - | 0 | 1 | 1 | 1 | 1 | - | - | - | - | - | ||||||
Assets Current | |||||||||||||||||||
| Accounts Receivable Net Current | 0 | 0 | - | 1 | - | 1 | - | 0 | 1 | - | - | 0 | - | ||||||
| Assets Current | 4 | 4 | 7 | 12 | 9 | 13 | 20 | 24 | 24 | 9 | 15 | 13 | 10 | ||||||
| Other Receivables | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Capitalized Contract Cost Net Current | - | - | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 4 | 3 | 3 | 4 | 2 | 2 | 3 | 2 | 3 | 2 | 2 | 2 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | - | - | - | - | - | ||||||
| Finite Lived Intangible Assets Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Equity Method Investments | - | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Capitalized Contract Cost Net Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Assets | 7 | 6 | 9 | 15 | 12 | 17 | 24 | 27 | 26 | 11 | 18 | 15 | 12 | ||||||
Liabilities And Stockholders Equity | |||||||||||||||||||
| Accounts Payable Current | 5 | 6 | 4 | 2 | 4 | 3 | 3 | 5 | 3 | 2 | 3 | 2 | 1 | ||||||
| Accrued Liabilities Current | 8 | 8 | 9 | 10 | 8 | 8 | 6 | 6 | 7 | 2 | 2 | 1 | 2 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | - | - | - | - | - | - | ||||||
Liabilities Current | |||||||||||||||||||
| Contract With Customer Liability Current | 0 | 0 | 19 | 20 | 20 | 21 | 21 | 21 | 20 | 19 | 19 | 19 | 15 | ||||||
| Liabilities Current | 17 | 20 | 35 | 37 | 42 | 31 | 31 | 33 | 29 | 24 | 25 | 22 | 18 | ||||||
| Notes Payable Current | - | - | 0 | 1 | 1 | - | 0 | 1 | 0 | 0 | 1 | 0 | 0 | ||||||
| Other Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Contract With Customer Liability Noncurrent | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 2 | 2 | - | - | - | - | - | - | ||||||
| Long Term Notes Payable | - | - | - | - | 3 | 11 | 11 | 5 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 18 | 21 | 37 | 39 | 48 | 45 | 44 | 40 | 30 | 25 | 26 | 24 | 23 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | 0 | - | - | - | - | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | |||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 171 | 169 | 169 | 166 | 153 | 153 | 153 | 152 | 152 | 122 | 121 | 114 | 106 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 8 | 7 | 6 | 5 | - | - | - | - | - | - | - | - | - | ||||||
| Retained Earnings Accumulated Deficit | -190 | -190 | -202 | -196 | -189 | -181 | -173 | -165 | -156 | -135 | -130 | -123 | -117 | ||||||
| Stockholders Equity | -12 | -15 | -28 | -24 | -36 | -28 | -20 | -13 | -4 | -13 | -9 | -9 | -11 | ||||||
| Liabilities And Stockholders Equity | 7 | 6 | 9 | 15 | 12 | 17 | 24 | 27 | 26 | 11 | 18 | 15 | 12 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 45 | 36 | 36 | 27 | 18 | 18 | 18 | 18 | 14 | 11 | 11 | 10 | 9 | ||||||
| Shares Outstanding | 45 | 36 | 36 | 27 | 18 | 18 | 18 | 18 | 14 | 11 | 11 | 10 | 9 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAridis Pharmaceuticals, Inc. (ARDS) — SEC Financial Statements & Analysis
Aridis Pharmaceuticals, Inc. (ARDS) is a pharmaceutical preparations company, incorporated in DE. Aridis Pharmaceuticals, Inc. trades on OTC as: ARDS. Aridis Pharmaceuticals, Inc. (ARDS)'s most recent SEC filing is a Form 10-Q for the period ended 2023-09-30, filed with the SEC on 2023-11-06. Based on that filing, Aridis Pharmaceuticals, Inc. carries a market cap of $3.82M, a P/E ratio of -3.35x, a P/B ratio of -0.32x, a P/S ratio of 0.17x, an enterprise value of $3.29M, and an EV/EBITDA multiple of -5.73x. On profitability, it posts an operating margin of -3.95%, a net margin of -5.11%, a Return on Equity (ROE) of 4.80%, and a Return on Assets (ROA) of -12.24%. Per share, it reports EPS of $-0.03, diluted EPS of $-0.03, free cash flow per share of $-0.48, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 680.42% year-over-year, net income growth of -96.91% year-over-year, and EPS growth of -98.54% year-over-year. On the balance sheet, it maintains a current ratio of 0.24x, a quick ratio of 0.03x, working capital of $-13.37M, a debt-to-equity ratio of -1.55x, a debt ratio of 2.81, an interest coverage ratio of -4.99x, free cash flow of $-17.93M (TTM), and net debt of $-535.00K. Figures sourced from SEC EDGAR.
- Market Cap
- $3.82M
- P/E TTM
- -3.35x
- EPS TTM
- $-0.03
- P/B TTM
- -0.32x
- ROE TTM
- 4.80%
- ROA TTM
- -12.24%
- Debt To Equity
- -1.55x
- Free Cash Flow TTM
- $-17.93M
- Net Revenue TTM Growth 1Y
- 680.42%
Data as of 2023-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aridis Pharmaceuticals, Inc. in?
Aridis Pharmaceuticals, Inc. (ARDS) operates in the Pharmaceutical Preparations industry.
What exchange does ARDS trade on?
Aridis Pharmaceuticals, Inc. (ARDS) trades on the OTC.
Where is Aridis Pharmaceuticals, Inc. incorporated?
Aridis Pharmaceuticals, Inc. is incorporated in DE.
When was Aridis Pharmaceuticals, Inc. (ARDS)'s most recent SEC filing?
Aridis Pharmaceuticals, Inc. (ARDS)'s most recent SEC filing is a Form 10-Q for the period ended 2023-09-30, filed with the SEC on 2023-11-06.
What is ARDS's market cap?
Aridis Pharmaceuticals, Inc. (ARDS) has a market capitalization of $3.82M as of 2023-09-30.
What is ARDS's EPS (earnings per share)?
Aridis Pharmaceuticals, Inc. (ARDS)'s trailing twelve month EPS is $-0.03 as of 2023-09-30.
What is ARDS's ROE (return on equity)?
Aridis Pharmaceuticals, Inc. (ARDS)'s trailing twelve month Return on Equity (ROE) is 4.80% as of 2023-09-30.
What is ARDS's ROA (return on assets)?
Aridis Pharmaceuticals, Inc. (ARDS)'s trailing twelve month Return on Assets (ROA) is -12.24% as of 2023-09-30.
What is ARDS's EV/EBITDA?
Aridis Pharmaceuticals, Inc. (ARDS)'s trailing twelve month EV/EBITDA is -5.73x as of 2023-09-30.